Tam Duc Heart Hospital (TTD) Q2 Profit Falls 25.6%, Cash Pile at 42% of Assets
This Aveluro analysis covers TTD on UPCOM in the Health Care sector. The classified event type is earnings miss, with negative sentiment and a deterministic market-impact score of 8.4/10. Aveluro classifies this story as a negative catalyst and risk signal for the affected stock. Source coverage came from CafeF - Doanh nghiệp, classified as a primary/top-tier source.
Key Facts
Caveat: Not investment advice. · How Aveluro computed this: Aveluro combines extracted event facts, source credibility, ticker context, and market data. Scores are deterministic research signals, not recommendations.
Overview
Tam Duc Heart Hospital (TTD), listed on UPCOM, reported a 25.6% year-on-year decline in Q2 2026 net profit to 21.37 billion VND, with first-half profit falling 23.3% to 34.7 billion VND. Revenue remained nearly flat at 399 billion VND for the six-month period. The hospital’s cash and deposits stood at 181 billion VND, equivalent to 42% of total assets, underscoring a conservative financial posture amid operational headwinds.
Key Facts
- Q2 2026 net profit: 21.37 billion VND, down 25.6% YoY.
- H1 2026 net profit: 34.7 billion VND, down 23.3% YoY.
- Q2 2026 revenue: 207.58 billion VND, down 5.77% YoY.
- Cash and deposits: 181 billion VND, or 42% of total assets (434 billion VND).
- Short-term receivables rose 67.8% to 23.5 billion VND; inventory increased 39% to 64.7 billion VND.
- Total liabilities: 89.39 billion VND as of June 30, 2026, up from 83.11 billion VND at year-start.
- TTD closed at 105,000 VND on July 28, 2026.
What Happened
Tam Duc Heart Hospital (CTCP Bệnh viện Tim Tâm Đức) released its Q2 2026 financial statements, revealing a 25.6% drop in net profit to 21.37 billion VND compared to the same period last year. Revenue fell 5.77% to 207.58 billion VND, while financial income rose 73.7% to 4.46 billion VND. However, selling expenses declined only marginally, and administrative expenses increased 7.57% to 18.95 billion VND, compressing operating profit.
The company attributed the profit decline to lower revenue combined with sticky costs, a shift in revenue mix toward higher-cost services (pharmacy, cardiac catheterization, and electrophysiology), and rising personnel expenses from periodic salary adjustments. Input costs for outsourced services also increased. For the first half, net profit totaled 34.7 billion VND, down 23.3% YoY, on nearly flat revenue of 399 billion VND.
Market Context
TTD trades on UPCOM and closed at 105,000 VND on July 28, 2026. The stock has been volatile amid the broader healthcare sector’s mixed performance. The hospital’s high cash ratio (42% of assets) contrasts with declining profitability, potentially signaling underinvestment in growth. The increase in receivables and inventory suggests working capital strain, while liabilities rose modestly.
Strategic Significance
TTD’s earnings miss highlights margin pressure in Vietnam’s private hospital sector, where cost inflation and regulatory constraints on drug pricing are squeezing profitability. The hospital’s large cash pile (181 billion VND) provides a cushion but also raises questions about capital allocation—whether it will be deployed for expansion, equipment upgrades, or returned to shareholders. The shift toward higher-cost cardiac procedures may improve long-term revenue quality but currently depresses margins. Investors should monitor whether management can stabilize costs and improve operational efficiency.
What to Watch
- Q3 2026 earnings release for signs of margin recovery or further deterioration.
- Any announcements regarding use of the 181 billion VND cash balance (dividends, share buybacks, or capex).
- Changes in receivables and inventory turnover as indicators of working capital management.
- Regulatory updates on drug pricing or medical service fees that could affect revenue mix.
- Potential M&A or partnership moves to expand service offerings or geographic reach.